|
1
|
Richards BL, Whittle SL and Buchbinder R:
Neuromodulators for pain management in rheumatoid arthritis.
Cochrane Database Syst Rev. 1:CD0089212012.PubMed/NCBI
|
|
2
|
Burness CB and McCormack PL: Capsaicin 8%
Patch: A review in peripheral neuropathic pain. Drugs. 76:123–134.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Matharu M: Cluster headache. BMJ Clin
Evid. 2010:12122010.PubMed/NCBI
|
|
4
|
Ito K, Nakazato T, Yamato K, Miyakawa Y,
Yamada T, Hozumi N, Segawa K, Ikeda Y and Kizaki M: Induction of
apoptosis in leukemic cells by homovanillic acid derivative,
capsaicin, through oxidative stress: Implication of phosphorylation
of p53 at Ser-15 residue by reactive oxygen species. Cancer Res.
64:1071–1078. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lau JK, Brown KC, Dom AM, Witte TR,
Thornhill BA, Crabtree CM, Perry HE, Brown JM, Ball JG, Creel RG,
et al: Capsaicin induces apoptosis in human small cell lung cancer
via the TRPV6 receptor and the calpain pathway. Apoptosis.
19:1190–1201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin J, Lin G, Huang H, Xu D, Yu H, Ma X,
Zhu L, Ma D and Jiang H: Capsaicin mediates cell cycle arrest and
apoptosis in human colon cancer cells via stabilizing and
activating p53. Int J Biol Sci. 10:285–295. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sarkar A, Bhattacharjee S and Mandal DP:
Induction of apoptosis by eugenol and capsaicin in human gastric
cancer AGS cells-elucidating the role of p53. Asian Pac J Cancer
Prev. 16:6753–6759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Díaz-Laviada I: Effect of capsaicin on
prostate cancer cells. Future Oncol. 6:1545–1550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang SP, Chen JC, Wu CC, Chen CT, Tang
NY, Ho YT, Lo C, Lin JP, Chung JG and Lin JG: Capsaicin-induced
apoptosis in human hepatoma HepG2 cells. Anticancer Res.
29:165–174. 2009.PubMed/NCBI
|
|
10
|
Clark R and Lee SH: Anticancer properties
of capsaicin against human cancer. Anticancer Res. 36:837–843.
2016.PubMed/NCBI
|
|
11
|
Hu F, Yang S, Zhao D, Zhu S, Wang Y and Li
J: Moderate extracellular acidification inhibits capsaicin-induced
cell death through regulating calcium mobilization, NF-kappaB
translocation and ROS production in synoviocytes. Biochem Biophys
Res Commun. 424:196–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee HK, Seo IA, Shin YK, Park JW, Suh DJ
and Park HT: Capsaicin inhibits the IL-6/STAT3 pathway by depleting
intracellular gp130 pools through endoplasmic reticulum stress.
Biochem Biophys Res Commun. 382:445–450. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhattacharya B, Mohd Omar MF and Soong R:
The Warburg effect and drug resistance. Br J Pharmacol.
173:970–979. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wilson JE: Isozymes of mammalian
hexokinase: Structure, subcellular localization and metabolic
function. J Exp Biol. 206:2049–2057. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mathupala SP, Ko YH and Pedersen PL:
Hexokinase II: Cancer's double-edged sword acting as both
facilitator and gatekeeper of malignancy when bound to
mitochondria. Oncogene. 25:4777–4786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
DeLaPaz RL, Patronas NJ, Brooks RA, Smith
BH, Kornblith PL, Milam H and Di Chiro G: Positron emission
tomographic study of suppression of gray-matter glucose utilization
by brain tumors. AJNR Am J Neuroradiol. 4:826–829. 1983.PubMed/NCBI
|
|
17
|
Ogawa H, Nagano H, Konno M, Eguchi H,
Koseki J, Kawamoto K, Nishida N, Colvin H, Tomokuni A, Tomimaru Y,
et al: The combination of the expression of hexokinase 2 and
pyruvate kinase M2 is a prognostic marker in patients with
pancreatic cancer. Mol Clin Oncol. 3:563–571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin Z, Gu J, Xin X, Li Y and Wang H:
Expression of hexokinase 2 in epithelial ovarian tumors and its
clinical significance in serous ovarian cancer. Eur J Gynaecol
Oncol. 35:519–524. 2014.PubMed/NCBI
|
|
19
|
Guzman G, Chennuri R, Chan A, Rea B,
Quintana A, Patel R, Xu PZ, Xie H and Hay N: Evidence for
heightened hexokinase II immunoexpression in hepatocyte dysplasia
and hepatocellular carcinoma. Dig Dis Sci. 60:420–426. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schreurs LM, Smit JK, Pavlov K, Pultrum
BB, Pruim J, Groen H, Hollema H and Plukker JT: Prognostic impact
of clinicopathological features and expression of biomarkers
related to (18)F-FDG uptake in esophageal cancer. Ann Surg Oncol.
21:3751–3757. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li YM, Lin Q, Zhao L, Wang LC, Sun L, Dai
MM, Luo ZM, Zheng H and Wu H: Pre-treatment metabolic tumor volume
and total lesion glycolysis are useful prognostic factors for
esophageal squamous cell cancer patients. Asian Pac J Cancer Prev.
15:1369–1373. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hong JH, Kim HH, Han EJ, Byun JH, Jang HS,
Choi EK, Kang JH and Yoo Ie R: Total lesion glycolysis using
(18)F-FDG PET/CT as a prognostic factor for locally advanced
esophageal cancer. J Korean Med Sci. 31:39–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mathupala SP, Ko YH and Pedersen PL:
Hexokinase-2 bound to mitochondria: Cancer's stygian link to the
‘Warburg Effect’ and a pivotal target for effective therapy. Semin
Cancer Biol. 19:17–24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Patra KC, Wang Q, Bhaskar PT, Miller L,
Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, et al:
Hexokinase 2 is required for tumor initiation and maintenance and
its systemic deletion is therapeutic in mouse models of cancer.
Cancer Cell. 24:213–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suh DH, Kim MA, Kim H, Kim MK, Kim HS,
Chung HH, Kim YB and Song YS: Association of overexpression of
hexokinase II with chemoresistance in epithelial ovarian cancer.
Clin Exp Med. 14:345–353. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peng Q, Zhou J, Zhou Q, Pan F, Zhong D and
Liang H: Silencing hexokinase II gene sensitizes human colon cancer
cells to 5-fluorouracil. Hepato-gastroenterology. 56:355–360.
2009.PubMed/NCBI
|
|
28
|
Jiang JX, Gao S, Pan YZ, Yu C and Sun CY:
Overexpression of microRNA-125b sensitizes human hepatocellular
carcinoma cells to 5-fluorouracil through inhibition of glycolysis
by targeting hexokinase II. Mol Med Rep. 10:995–1002. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang L, Xiong H, Wu F, Zhang Y, Wang J,
Zhao L, Guo X, Chang LJ, You MJ, Koochekpour S, et al: Hexokinase
2-mediated Warburg effect is required for PTEN- and
p53-deficiency-driven prostate cancer growth. Cell Reports.
8:1461–1474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang D, Wang TY, Li HC, Wei JC and Song
JX: Prognostic significance of PTEN expression in esophageal
squamous cell carcinoma from Linzhou City, a high incidence area of
northern China. Dis Esophagus. 20:491–496. 2007. View Article : Google Scholar : PubMed/NCBI
|
